Floatz logo

FILGRASTIM

Stage IV Pancreatic Cancer

General Oncology, Inc.protein_peptidePhase 2Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Stage IV Pancreatic Cancer cohort.

Asset / SponsorPhaseRating
Veliparib
National Cancer Institute (NCI)
Phase 2BB
Cediranib
M.D. Anderson Cancer Center
Phase 3BB
azd6244
National Cancer Institute (NCI)
Phase 2BB
Sorafenib
HonorHealth Research Institute
Phase 2BB
PREDNISONE TABLETS
OHSU Knight Cancer Institute
Phase 2BB

View all 20 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →